CSIMarket


Exact Sciences Corporation  (EXAS)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare


 

Exact Sciences Corporation

EXAS's Financial Statements and Analysis



Exact Sciences Corporation narrowed forth quarter of 2023 net loss per share of $-0.27 compare to net loss per share of $-0.70 recorded in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.27 $  672 Mill
$+0.43     $+125M     +22.81 %



Exact Sciences's Revenue rose by 22.81 % in forth quarter of 2023 (Dec 31 2023) year on year, to $672 million and advanced by 6.63 % sequentially.


Exact Sciences is

More on EXAS's Income Statement



Exact Sciences's in theforth quarter of 2023 recorded net loss of $-49.766 million, an improvement compare to net loss of $-127.745 million in IV. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $0.794 million in the previous quarter.

More on EXAS's Growth

Exact Sciences Inventories
Inventories grew by 7.79 % to $127 million from IV. Quarter a year ago, sequentially inventories fell by -4.04 %. EXAS's Cash flow In the forth quarter of 2023 company's net cash flow was $15 million, capital expenditures grew by -72.876-52.08%, to $-35 millions compare to same quarter a year ago

More on EXAS's Cash flow Statement


Exact Sciences Corporation does not pay out common stock dividend.

In trailing twelve-month period Exact Sciences Corporation earned $ 0.86 cash per share, on a free-cash flow basis .

Book value grew by 2.67 % sequentially to $17.41 per share.
Tangible Book value grew to $ -6.16 per share from $ -6.29.

Company repurchased 3.41 million shares or 1.85 % in Dec 31 2023.


More on EXAS's Dividends

 Market Capitalization (Millions) 11,786
 Shares Outstanding (Millions) 181
 Total Debt (Millions $) 2,364
 Revenue (TTM) (Millions $) 2,532
 Net Income (TTM) (Millions $) -204
 Cash Flow (TTM) (Millions $) 367
 Capital Exp. (TTM) (Millions $) -124
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 5,361




Exact Sciences Corporation does not pay out common stock dividend.

In trailing twelve-month period Exact Sciences Corporation had $ 0.86 cash flow per share, on a free-cash flow basis .

Book value grew by 2.67 % sequentially to $17.41 per share.
Tangible Book value grew to $ -6.16 per share from $ -6.29.

Company repurchased 3.41 million shares or 1.85 % in Dec 31 2023.


More on EXAS's Balance Sheets

 Market Capitalization (Millions) 11,786
 Shares Outstanding (Millions) 181
 Total Debt (Millions $) 2,364
 Revenue (TTM) (Millions $) 2,532
 Net Income (TTM) (Millions $) -204
 Cash Flow (TTM) (Millions $) 367
 Capital Exp. (TTM) (Millions $) -124
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 5,361
   


  News about Exact Sciences Corporation Earnings

Exact Sciences Corporation Surpasses Revenue Expectations, Yet Profitability Remains Elusive



The Medical Laboratories company, Exact Sciences Corporation, has reported impressive financial results in its most recent fiscal period. With a surge in revenue of 22.81% to $672.22 million from the same quarter a year prior, combined with a significant reduction in net loss per share, the company seems to be on a positive trajectory. Additionally, a rise in accounts receivable and reduced inventories signal a potential increase in demand. This article aims to interpret these financial results, highlighting the possible impacts on Exact Sciences Corporation going forward.
1. Improved Revenue:
Exact Sciences Corporation's revenue experienced substantial growth during the last fiscal year, r...

Exact Sciences Corporation Surges to New Heights: Breakthrough Revenue Growth in Q3 2023

A Surge in Revenue Fails to Boost Income: Analyzing Exact Sciences Corporation's Q3 2023 Financial Report
As the third quarter of 2023 came to an end, Exact Sciences Corporation released their financial report, revealing that despite a remarkable surge in revenue, the company's income remained stagnant. The earnings per share stood at break-even at $0.00, which must have disappointed investors hoping for a more substantial growth in profitability.
However, it is important to note that the revenue for Exact Sciences Corporation took a significant leap of 22.53% compared to the same period last year, reaching an impressive $630.40 million. This rise in revenue puts Exact Sciences Corporation ahead of m...

Exact Sciences Corporation Witnesses a Remarkable 21.046% Revenue Surge to $626.92 Million in Q2 2023

The financial results for Exact Sciences Corporation (EXAS) in the second quarter of 2023 indicate both positive and negative aspects for the company. On one hand, there was a significant surge in revenue, with a growth rate of 21.046% compared to the same period in the previous year. This resulted in a total revenue of $626.92 million, showcasing a strong performance in sales.
However, the company reported a loss of $-0.45 per share, representing a sequential increase in the deficit from the previous quarter's $-0.42 per share. Despite the boost in revenue, EXAS was unable to turn a profit in this particular quarter. This loss per share might be a concern for investors, especially considering the increa...


Date modified: 2024-02-22T09:21:54+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com